These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10939947)

  • 1. Pseudomonas survival strategies in cystic fibrosis.
    LeClerc JE; Cebula TA
    Science; 2000 Jul; 289(5478):391-2. PubMed ID: 10939947
    [No Abstract]   [Full Text] [Related]  

  • 2. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants.
    Oliver A; Baquero F; Blázquez J
    Mol Microbiol; 2002 Mar; 43(6):1641-50. PubMed ID: 11952911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation.
    Mena A; Smith EE; Burns JL; Speert DP; Moskowitz SM; Perez JL; Oliver A
    J Bacteriol; 2008 Dec; 190(24):7910-7. PubMed ID: 18849421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis.
    Evans TJ
    Future Microbiol; 2015; 10(2):231-9. PubMed ID: 25689535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The miaA mutator phenotype of Escherichia coli K-12 requires recombination functions.
    Zhao J; Leung HE; Winkler ME
    J Bacteriol; 2001 Mar; 183(5):1796-800. PubMed ID: 11160115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.
    Maciá MD; Blanquer D; Togores B; Sauleda J; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3382-6. PubMed ID: 16048951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
    Smith EE; Buckley DG; Wu Z; Saenphimmachak C; Hoffman LR; D'Argenio DA; Miller SI; Ramsey BW; Speert DP; Moskowitz SM; Burns JL; Kaul R; Olson MV
    Proc Natl Acad Sci U S A; 2006 May; 103(22):8487-92. PubMed ID: 16687478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections.
    Nguyen D; Singh PK
    Proc Natl Acad Sci U S A; 2006 May; 103(22):8305-6. PubMed ID: 16717189
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.
    Warren AE; Boulianne-Larsen CM; Chandler CB; Chiotti K; Kroll E; Miller SR; Taddei F; Sermet-Gaudelus I; Ferroni A; McInnerney K; Franklin MJ; Rosenzweig F
    Infect Immun; 2011 Dec; 79(12):4802-18. PubMed ID: 21930755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections.
    Imamovic L; Ellabaan MMH; Dantas Machado AM; Citterio L; Wulff T; Molin S; Krogh Johansen H; Sommer MOA
    Cell; 2018 Jan; 172(1-2):121-134.e14. PubMed ID: 29307490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection.
    Oliver A
    J Cyst Fibros; 2015 Jul; 14(4):e1-2. PubMed ID: 25563521
    [No Abstract]   [Full Text] [Related]  

  • 12. Is infection with hypermutable Pseudomonas aeruginosa clinically significant?
    Auerbach A; Kerem E; Assous MV; Picard E; Bar-Meir M
    J Cyst Fibros; 2015 May; 14(3):347-52. PubMed ID: 25308183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic Fibrosis Lung Function Decline after Within-Host Evolution Increases Virulence of Infecting
    Jorth P; Durfey S; Rezayat A; Garudathri J; Ratjen A; Staudinger BJ; Radey MC; Genatossio A; McNamara S; Cook DA; Aitken ML; Gibson RL; Yahr TL; Singh PK
    Am J Respir Crit Care Med; 2021 Mar; 203(5):637-640. PubMed ID: 33137262
    [No Abstract]   [Full Text] [Related]  

  • 14. The MutS C terminus is essential for mismatch repair activity in vivo.
    Calmann MA; Nowosielska A; Marinus MG
    J Bacteriol; 2005 Sep; 187(18):6577-9. PubMed ID: 16159793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection: Response to Dr. Oliver.
    Bar-Meir M
    J Cyst Fibros; 2015 Jul; 14(4):e3. PubMed ID: 25592655
    [No Abstract]   [Full Text] [Related]  

  • 16. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice.
    Mena A; Maciá MD; Borrell N; Moya B; de Francisco T; Pérez JL; Oliver A
    J Bacteriol; 2007 May; 189(9):3665-8. PubMed ID: 17307847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.
    Pitt TL
    J R Soc Med; 1986; 79 Suppl 12(Suppl 12):13-8. PubMed ID: 2425090
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudomonas aeruginosa infection and cystic fibrosis.
    Kato K; Takayama T
    Lancet; 2002 Jan; 359(9302):262. PubMed ID: 11812595
    [No Abstract]   [Full Text] [Related]  

  • 19. Interspecies recombination and mismatch repair. Generation of mosaic genes and genomes.
    Matic I; Taddei F; Radman M
    Methods Mol Biol; 2000; 152():149-57. PubMed ID: 10957975
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptides, Pseudomonas aeruginosa, polysaccharides and lipopolysaccharides--players in the predicament of cystic fibrosis patients.
    Pier GB
    Trends Microbiol; 2000 Jun; 8(6):247-50; discussion 250-1. PubMed ID: 10838574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.